Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Haziz AlBiladi"'
Autor:
Mohammed A Babatin, Abdullah S AlGhamdi, Abdullah M Assiri, Haziz AlBiladi, Hammad S AlOthmani, Mohammed H Mogharbel, Wedad Mahallawi, Tarik Asselah, Faisal M Sanai
Publikováno v:
The Saudi Journal of Gastroenterology, Vol 25, Iss 1, Pp 55-60 (2019)
Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) combination is administered for 12 to 24 weeks to treat hepatitis C virus (HCV); guidelines recommend 8 weeks treatment duration for HCV genotype (GT) 1 infection based on the patient's baseline charac
Externí odkaz:
https://doaj.org/article/a76293c80b0847d292dd9cba0fe5d906
Autor:
Abdullah S. Alghamdi, Hammad S. Alothmani, Faisal M. Sanai, Mohammed H Mogharbel, Mohammed A. Babatin, Haziz Albiladi, Tarik Asselah, Wedad Mahallawi, Abdullah M. Assiri
Publikováno v:
Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association
The Saudi Journal of Gastroenterology, Vol 25, Iss 1, Pp 55-60 (2019)
The Saudi Journal of Gastroenterology, Vol 25, Iss 1, Pp 55-60 (2019)
Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) combination is administered for 12 to 24 weeks to treat hepatitis C virus (HCV); guidelines recommend 8 weeks treatment duration for HCV genotype (GT) 1 infection based on the patient's baseline charac
Autor:
Waleed Al-Hamoudi, Khalid Alswat, Ayman A. Abdo, Waleed A. Mousa, Abduljaleel M. Alalwan, Yaser Dahlan, Abdulrahman Aljumah, Adnan AlZanbagi, Abdallah AlMousa, Hamdan S. Alghamdi, Abdelrahman Awny, Ashwaq Alsahafi, Mohammed AlJawad, Mohamed A. Babatin, Abdullah M. Assiri, Ibrahim Altraif, Haziz Albiladi, Faisal M. Sanai, Nawaf H Almutairi, Ali Albenmousa, Mohammed S. AlSaleemi, Abdullah S. Alghamdi, Hammad S. Alothmani
Publikováno v:
Journal of Infection. 76:536-542
Summary Limited clinical trial data has shown high efficacy of co-formulated ledipasvir/sofosbuvir (LDV/SOF) in the treatment of hepatitis C virus (HCV) genotype (GT)-4 infected cirrhotic patients. We assessed real-world safety and efficacy of LDV/SO
Autor:
Haziz Albiladi, Abdullah S. Alghamdi, Mohammed Almugharbal, Khalid I. Bzeizi, Mohammed A. Babatin, Abdulla Alaseeri, Hammad S. Alothmani, Faisal M. Sanai, Ali Albenmousa, Ashwaq Alsahafi, Mahdi Aljarodi
Publikováno v:
Journal of clinical gastroenterology. 52(5)
INTRODUCTION The combination of sofosbuvir (SOF) with simeprevir (SMV) or daclatasvir (DCV) is very effective in treating hepatitis C virus (HCV) infection, particularly genotype (GT) 1. However, the data on GT4 are very limited. We aimed to determin